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Background: ‘Neuromarketing’ is a term that has often been used in the media in recent years. These public
discussions have generally centered around potential ethical aspects and the public fear of negative consequences
for society in general, and consumers in particular. However, positive contributions to the scientific discourse from
developing a biological model that tries to explain context-situated human behavior such as consumption have
often been neglected. We argue for a differentiated terminology, naming commercial applications of neuroscientific
methods ‘neuromarketing’ and scientific ones ‘consumer neuroscience’. While marketing scholars have eagerly
integrated neuroscientific evidence into their theoretical framework, neurology has only recently started to draw its
attention to the results of consumer neuroscience.
Discussion: In this paper we address key research topics of consumer neuroscience that we think are of interest for
neurologists; namely the reward system, trust and ethical issues. We argue that there are overlapping research
topics in neurology and consumer neuroscience where both sides can profit from collaboration. Further,
neurologists joining the public discussion of ethical issues surrounding neuromarketing and consumer neuroscience
could contribute standards and experience gained in clinical research.
Summary: We identify the following areas where consumer neuroscience could contribute to the field of
neurology:
First, studies using game paradigms could help to gain further insights into the underlying pathophysiology of
pathological gambling in Parkinson’s disease, frontotemporal dementia, epilepsy, and Huntington’s disease.
Second, we identify compulsive buying as a common interest in neurology and consumer neuroscience. Paradigms
commonly used in consumer neuroscience could be applied to patients suffering from Parkinson’s disease and
frontotemporal dementia to advance knowledge of this important behavioral symptom.
Third, trust research in the medical context lacks empirical behavioral and neuroscientific evidence. Neurologists
entering this field of research could profit from the extensive knowledge of the biological foundation of trust that
scientists in economically-orientated neurosciences have gained.
Fourth, neurologists could contribute significantly to the ethical debate about invasive methods in neuromarketing
and consumer neuroscience. Further, neurologists should investigate biological and behavioral reactions of
neurological patients to marketing and advertising measures, as they could show special consumer vulnerability
and be subject to target marketing.
Keywords: Neuromarketing, Neurology, Consumer neuroscience, Trust, Reward, Ethics, Pathological gambling,
Compulsive buying* Correspondence: andrija.javor@akh.linz.at
1Department of Neurology and Psychiatry, Linz General Hospital,
Krankenhausstrasse 9, 4021 Linz, Austria
Full list of author information is available at the end of the article
© 2013 Javor et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
Javor et al. BMC Neurology 2013, 13:13 Page 2 of 12
http://www.biomedcentral.com/1471-2377/13/13Background
Scientific development in recent years is characterized by
an expansion in the application of different and mul-
tidisciplinary research modalities in order to answer the
various questions of a given scientific field. Of particular
interest is the explosion in the use of neuroscientific me-
thods, ostensibly to better understand human behavior in
various contexts. This has led to the creation of the term
‘neuroculture’ [1], to refer to new scientific branches com-
bining neuroscience with other scientific branches, arts or
humanities, examples of this phenomenon include neuro-
philosophy (e.g. [2]) or neurotheology (e.g. [3]). Similarly,
but in an even more pejorative sense, Tallis [4] coined the
term ‘neuromania’ to refer to a headlong rush by seem-
ingly all fields of study to embrace neuroimaging, and
explain all human phenomena in terms of brain activity.
Yet while Tallis [4], and others critical of the embracing of
neuroimaging by various fields of study present powerful
caveats against the unquestioning acceptance that human
life in all its complexity can be reduced to brain activity, it
is undeniable that – when applied properly – neuroima-
ging has much to offer as an addition to existing scientific
tools, techniques, and frameworks [5].
Of particular interest is brain imaging research in the
economic and business disciplines. Indeed, economists
were amongst the first social scientists to recognize the
potential of neuroimaging, with the development of neu-
roeconomics [6-12]. Soon after the first neuroeconomic
papers had been published, marketing scholars discovered
the potential of neuroscientific methods as a new research
approach beside the classical qualitative and quantitative
methodological spectrum in the social sciences. Early on
in the field’s development, the term ‘neuromarketing’ re-
search was suggested in order to categorize studies in the
interdisciplinary field between economics, psychology,
biology and medicine [13]. However, in the ensuing dec-
ade, multiple definitions of neuromarketing appeared to
develop, even as neuroscientific and radiological advances
expanded the array of tools available to researchers in this
fledgling field [14-16].
Generally speaking, neuroscientific methods are used
to study consumer behavior and the decision-making
processes in purchasing acts [17], to better understand
psychological phenomena and emotions in purchase
decisions, as well as provide a more comprehensive as-
sessment of the efficacy of marketing phenomena like
advertising, consumer competitions, and product place-
ment, by analyzing the underlying neurobiology [18].
Such studies are per se purely academic, although they
clearly try to develop and derive recommendations for
practical marketing. Independently, there are many busi-
nesses offering neuroscientific methods under the um-
brella term ‘neuromarketing’. Often, the services offered
by such firms, and their explanatory power, appearexaggerated in advertising and one only has to have a
cursory understanding of neurophysiology to see that
many of the outlandish claims made in the popular press
about how neuroimaging can identify complex phenom-
ena such as ‘love’, or behaviors such as purchasing, to be
far overblown [19]. A recent study identified over 150 such
companies [20]. An analysis of 16 companies identified
through an internet search revealed that 5 of them offered
fMRI, 9 EEG and 12 Galvanic-Skin response and other tests
of the autonomic nervous system as methods [21].
Of course, the application of neurophysiological methods
as adjuvant instruments to behavioral data in marketing re-
search is not entirely new, but has attained media presence
in last decade by the use of easily-discussed imaging meth-
ods such as functional magnetic resonance imaging (fMRI),
and the special influence that brain images have on non-
neuroscientists [22]. In 2008, Hubert and Kenning reported
more than 800,000 Google hits for the term ‘neuromarket-
ing’ [23], and in 2012, the same search yields over 1.4 mil-
lion hits, underlining the continuing interest in this topic.
This development has further led to a discussion about
ethical aspects of neuromarketing not only in scientific
communities, but also in the general media [24,25]. Sud-
denly, journalists and by extension consumers appear to
fear that market researchers might be able to analyze their
private thoughts and emotions during purchase, and even
be able to influence them to buy (e.g. [26]). This fear is
not new though, and appears to be broadly similar to
earlier fears over subliminal advertising (for an overview
see [27]), even though this idea was later debunked (e.g.
[28]). Of course, traditional market research has always
been interested in analyzing and predicting purchase
behaviors, but the advent of high-profile neuroimaging
studies seems to have driven an explosion in public atten-
tion. Given the lack of knowledge on how experimental
studies including marketing research are in fact performed,
the general public are easily frightened. These ethical
concerns have been further inflamed by the foundation of
more and more enterprises (especially in the United States)
offering neuromarketing as a service.
Unfortunately, debates over neuromarketing tend to lack
a differentiation between scientific and commercial for-
profit applications [29]. Especially in the public ethical
discussion, it is important to distinguish academic studies
that use neuroscientific methods from those purely for the
purposes of commercial marketing. It is not taken into
consideration, that scientific studies often focus on the
consumer’s point of view, while commercial ones try to
apply findings in order to sell a product. In particular,
human beings do not act in a vacuum, and human beha-
viors are almost always context-laden. Much human
behavior occurs within a consumption context, and it has
been argued that incorporating such a context to neuro-
scientific work can also be of significant benefit [5,19,29].
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disciplinary character. Knowledge from marketing manage-
ment is tied together with psychological knowledge and
different medical fields (above all neurology, psychiatry and
radiology). As the general media mostly address commer-
cial marketing when reporting about neuromarketing, it is
essential to decouple these two entities and to controvert
the mechanistic public opinion about the brain-behavior re-
lationship by terming the scientific branch ‘consumer
neuroscience’ [14,19,20]. A similar debate about adding the
‘neuro-’prefix to other behavioral sciences and the conse-
quences of this ‘neuromania’ has been led lately by several
authors in leadership research [14,19,30].
Furthermore, among scientists and journalists, there is
an ambiguous view of neuromarketing. Beside a group of
advocates, who represent the opinion that neuromarketing
would lead to product improvement and therefore is bene-
ficial for consumers [24,25], there are numerous critics
[31-33]. For example, an editorial in ‘Nature Neuroscience’
stated that: ‘Neuromarketing is little more than a new fad
exploited by scientists and marketing consultants to blind
corporate clients with science.’ [34,35]. Hence, we strongly
suggest a discussion of both what neuromarketing can
and cannot do, and also what it should and should not do,
involving experts from both business and neuroscientific
research as well as ethicists and philosophers. Willingham
and Dunn [36] elaborated ways of integrating brain im-
aging data into social psychology theory. A similar synthe-
sis of brain imaging data and marketing theory still has to
be developed. The results of such a discussion could then
be presented to the public and would lead to an informed
public view of neuromarketing.
Research in the field of what was termed above ‘con-
sumer neuroscience’ has on the other hand generally been
positively accepted within the academic community. How-
ever, while marketing scholars have eagerly integrated
neuroscientific evidence into their theoretical frameworks,
medicine is reluctant to adopt the results of consumer
neuroscience. First attempts to transfer knowledge be-
tween neuroeconomics and psychiatry have been recently
published [37], but it is clear that a joint discussion of how
knowledge gained in ‘consumer neuroscience’ can contri-
bute to a broader field of science, including especially
biology, neuroscience, psychiatry and neurology, is still
scarce. Despite this, findings from consumer neuroscience
studies are significantly contributing to all behavioral
sciences, especially by focusing on the interaction of cog-
nitions and emotions in human behavior [38-40].
Discussion
As such, the results of consumer neuroscience research
can be fruitful for both scientific and clinical neurology for
a number of reasons. Behavior has always been a major
topic in neurological and psychiatric research and has ledto the subspecialty of behavioral neurology, which man-
ages the diagnosis of, and therapy for, behavioral symp-
toms of neurological disorders, e.g. dementia, depression,
psychosis, anxiety, obsessive-compulsive disorder, atten-
tion deficit/hyperactivity disorder, autism, and agitation
through neuropsychological and neurophysiological meth-
ods (including neuroimaging) [41]. Further, human behav-
ior and the activities of daily living (ADL) are included in
several diagnostic classifications and rating scales (e.g.
ICD-10, DSM IV, Schwab and England activities of daily
living scale). Consumer behavior research is considered a
behavioral science and studies humans in these daily acti-
vities and in real-world settings. Neuroeconomics and
consumer neuroscience investigate neural correlates of
human behavior related to job performance, social and
consumption behavior. Behavioral neurology may obtain a
more comprehensive understanding of human behavior by
incorporating insights from interdisciplinary approaches
like consumer neuroscience, that analyze behavior relevant
to the real world (see also [42]).
Consumer neuroscience has so far studied a large
number of neurobiologically-oriented topics, and as such
a complete review would be out of our present scope.
Rather, we chose to concentrate on three topics that ap-
pear to be of most relevance to neurologists. We focus
on (1) the reward system and its relations to brand pre-
ference and decision-making in purchasing, as it plays
an important role in several neurological diseases and
their behavioral symptoms. Further, we explore (2) the
neurobiology of trust, as it is the basis of every patient-
physician relationship and therefore of special interest to
any physician. Finally, we include a discussion of (3) the
ethical aspects of neuromarketing, since they dominate
public debate in this field.
The three key topics will be briefly summarized and
discussed in terms of their relevance to neurology in
subsequent sections of this paper. In doing so, we try to
make clear that the ecologically-valid research settings
available in marketing research contexts can add signifi-
cantly to neurology. As such, on the one hand, the find-
ings of consumer neuroscience that we present in this
paper might initiate further neurological and clinical re-
search in an interdisciplinary setting. On the other hand,
neurologists might be increasingly interested in joining
the public discussion about neuromarketing and its eth-
ical concerns. Both outcomes would be of significant
benefit to both scientific research and general social pro-
gress. The paper aims at providing the basis for an
enhanced two-way discussion instead of the one-way
path currently active.
Consumer neuroscience and the reward system
Two major brain systems are considered to be fundamen-
tal to almost all human behavior; the reward approach
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[43,44]. The neurobiology of the reward system is based
on the meso-limbic pathway, which extends from the ven-
tral tegmental area (VTA), through the nucleus accum-
bens (NACC) and the limbic system, to the orbitofrontal
cortex (OFC), while anticipation of loss, pain or punish-
ment activates the insula [45-48], for a review see [49,50].
Differential roles for these brain areas have been recently
detected and are summed up as the ‘Schultz Theory’ [51].
The nucleus accumbens seems to play a role as an integra-
tion site, receiving impulses from the OFC, which repre-
sents reward expectations, the amygdala (responsible for
reward conditioning), and dopamine neurons, all of which
play a role in reward prediction. The VTA and substantia
nigra show a high density of dopaminergic neurons. Brain
stimulation studies have shown that activation of these
dopaminergic systems leads to feelings of ‚well being’ [52].
Outputs of the striatum to the VTA code for mismatch
between predictors and reward.
Behavior is closely related to the reward system. In ani-
mals, basic rewards like food, drink and sexuality are pre-
dominant goals to be achieved through behavior. However,
in humans more abstract forms like financial and social
rewards (success, social status, culture etc.), or drugs that
interfere with the neurophysiology of the reward system,
are also main targets. In addition, certain physical objects,
like cars [53] or money [54] can be rewarding. There is a
considerable inter-individual variance in the sensitivity to
reward stimuli [55]. In classical marketing as well as in
consumer neuroscience, major research topics include the
purchasing act and how this behavior is influenced, for
example by the preference for a certain brand, although
how brands effect consumer decisions is still a matter of
debate [56-58].
The neurobiological basis of brand preference has been
a research topic from the beginning of consumer neuro-
science, and remains so today. The dorsolateral prefrontal
cortex (DLPFC) is thought to be prominently active in the
representation and integration of goals and reward infor-
mation [59] and might initiate, through connections to the
mesolimbic system, reward-motivated behavior [60]. The
function of the ventromedial prefrontal cortext (VMPFC)
is however still debated in neuroscience literature. Most
authors suggest an important role in decision-making,
especially in choice tasks [61].
In consumer neuroscience the VMPFC is studied in the
context of brand preference. Paulus and Frank [62] postu-
lated that this region plays a key role in preference judg-
ments, while other authors presented data challenging this
hypothesis [63]. McClure et al. [64] examined the brand
preference for Pepsi and Coca-Cola drinks by means of
fMRI. Finding that in blind tastings, no difference between
the response in the brain appeared. However, in open tast-
ings (when subjects could see the brand), limbic structureslike the hippocampus and the DLPFC showed enhanced
activity, presumably according to brand preference. One
conclusion of this experiment is that preference is pro-
cessed in different brain areas depending on the source of
information: the VMPFC is active when preferences were
based on sensory information only (taste), while the hippo-
campus, the DLPFC and the midbrain showed enhanced
response when judgments were based on both sensory
inputs and the brand. This study, among others, suggests
the importance of emotionalizing for the success of a
brand [54] and hints at subconscious and purely emotional
aspects involved in consumption behavior.
Purchasing is a behavior at least partly determined by
the reward system. The pros (reward of buying) and cons
(displeasure of paying) have to be weighed up against each
other in the sense of a hedonic competition between
pleasure and pain [65]. Purchasing acts are preceded by an
activation of the nucleus accumbens, which correlates
with product preferences, while high prices can lead to an
increase of insula activation in the sense of an anticipation
of loss [66]. An increase in the BOLD (blood oxygen level
dependent) response measured by fMRI in the insula cor-
tex can further precede a negative product choice [66-70].
Thus, preferred brands can be seen as a reward stimulus,
and may impair strategic reasoning, probably by a reduced
activity of the DLPFC [71]. These preferred brands also
seem to activate the reward system more than others [72],
while the price of a product directly affects neural reward
signals through an increased expectation [73]. Read in
conjunction with the previously mentioned article of
Knutson et al. [66] a high price can therefore either lead
to an anticipation of loss, or to a reward through a high
anticipation of utility.
A paradigm commonly used in animal research is condi-
tioned preference. Here, a preference for a neutral stimulus
is created by rewards. Johnsrude et al. [74] adapted this
approach to human volunteers with unilateral anterior
temporal lobe resections, and by doing so created evidence
for a role of the amygdala in reward conditioning. A rele-
vant question in this context concerns the degree to which
unconscious stimuli can influence behavior [75]. Although
there are theories regarding how brand preference is built
over time [76], a functional brain imaging study about how
brand preference can be conditioned by marketing tools
such as advertising has, to the best of our knowledge, not
been realized yet. While such a study is certainly challen-
ging concerning the experimental design, it would be an
interesting field for future research. In fact, recent fMRI-
studies [77,78] indicate celebrity endorser credibility has a
modulating effect on product preferences and memory.
Celebrity endorsement is a widely used technique in adver-
tising, hence the results of these fMRI-studies could build
the basis for a more detailed investigation of advertising’s
effects on both product and brand preferences.
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brand preference, general and consumer neuroscience
have gained significant knowledge about the reward
system, frontal brain regions and their relevance to deci-
sion-making. Although there are lesional studies on brand
preference and purchasing behavior, a research gap seems
to exist, as how neurological diseases affect behavior and
decisions in this context.
Implications for neurology
The reward system is related to a set of behavioral ano-
malies that are frequently found in neurological diseases,
like impulsive-compulsive disorders, including pathological
gambling and compulsive buying. As there are both
neurologists and consumer neuroscientists involved in
research of these behavioral patterns, we think that these
contexts offer an opportunity for interdisciplinary research.
Pathological gambling is characterized by a loss of control
over gambling, deception about the extent of one’s involve-
ment with gambling, family and job disruption, theft, and
chasing losses, or the effort to win back money lost while
gambling [79]. It is frequent in Parkinson’s disease [80],
restless legs syndrome [81], frontotemporal dementia [82],
epilepsy [83] and Huntington’s disease [84] and might be
the consequence of a neurodegenerative or iatrogenic
impairment of reward pathways [85,86]. Pathological gam-
bling is also associated with a reduced activation of the
mesolimbic reward system in functional brain imaging
[87]. It has already been suggested that psychiatry should
adopt findings from neuroeconomics, especially in patho-
logical gambling. ‘. . .Experimental paradigms derived from
NE [neuroeconomics], such as economic exchange games,
can be usefully applied to understand psychiatric dis-
orders. . .’ [88]. We argue that behavioral neurologists
should investigate patients suffering from a neurological
disease with a higher incidence of pathological gambling
using game paradigms of neuroeconomics and para-
digms involving brands and purchasing acts of ‘con-
sumer neuroscience’ to learn more about the underlying
pathophysiology.
Compulsive buying is a highly debated disorder in the
psychiatric field, as its classification as a behavioral ad-
diction or an impulse control disorder is still unclear
[89]. Compulsive buying is defined as ‘a tendency to be
preoccupied with buying that is revealed by repetitive
buying and a lack of impulse control over buying’, with
an incidence of 5.8% in the United States [90]. It is con-
sidered to be related to the reward system [91]. A higher
incidence for this behavior has been reported in patients
suffering from Parkinson’s disease [80] and frontotem-
poral dementia [92]. Further, there is a co-occurrence
between depression and impulsive-compulsive buying
[93], which supports the theory of an impaired reward
system in depressed patients [94]. A recent consumerneuroscience study was able to show a difference in the
activation of the reward and loss/pain avoidance system
between compulsive and non-compulsive buyers. The
former showed a higher activity in the nucleus accumbens
and a lower activation of the insula during the presenta-
tion of a product and its price than non-compulsive
buyers [95]. A study about the responsiveness to brands
and advertising of neurological patients suffering from
compulsive buying behavior could further advance know-
ledge in behavioral neurology.
Trust
Trust is a basic human phenomenon, essential for humans
if they are to live among unknown others, and therefore is
vital for the functioning of modern societies [96,97]. Mul-
tiple definitions of trust exist, but most somehow refer to
trust as a behavior [98]. Trust behavior involves the volun-
tary placement of resources at the disposal of a trustee
with no enforceable commitment from the trustee. This
situation can either be beneficial for both sides, if the
trustee reciprocates, or lead to loss for the trustor if the
trustee is opportunistic. Trust thereby involves the risk of
betrayal. Recent research indicates that distrust is unlikely
to be simply the absence of trust, but a distinct phenom-
ena itself, which makes it possible to have a certain degree
of trust and distrust at the same time [99]. However, one
of the most challenging tasks in research involving human
behavior is the operationalization of trust/distrust. In neu-
roeconomic research the trust game and the evaluation of
trustworthiness of faces are common methods [100,101]a.
A detailed review of literature on trust is well beyond
the present scope. In what follows then, we give an over-
view of biologically-orientated literature on trust. For
greater detail we refer readers to a number of reviews
that can be read in conjunction with the present piece
(e.g. [102-104]).
Trusting an unknown person requires an individual to
perform a number of stepwise evaluations. Each of these
steps is associated with distinct brain areas.
 Trustworthiness evaluation: By visual perception of
key anatomic features of the other person’s face his
or her trustworthiness is assessed. This can lead to
uncertainty, ambiguity or fear. During this process
the amygdala and the insula cortex show activation
in fMRI scans [105-107].
 Prediction of the other person’s future action: At this
stage, questions as to the likelihood of trust
reciprocation, deception, prior knowledge of this
person, or prior experience of trusting unknowns
are evaluated. Here, theory-of-mind regions such as
the paracingulate and the medial prefrontal cortex,
as well as memory regions (e.g. amygdala and
hippocampus) are active [108,109].
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neurobiological reward system is relevant, as the
individual assesses the likely reward of their trusting
behavior. This system is discussed above (see also e.
g. [106,107,110]).
 Processing of cognitive conflict is associated with
activation in the anterior cingulate cortex [104-106].
In trust situations this area is active, because the risk
of betrayal and the possible reward of a beneficial
outcome have to be weighed up against each other.
Besides these specific brain areas, several neurotrans-
mitters and hormones modulate trusting behavior (for a
review see [104]). Oxytocin, a neuropeptide that plays an
important role in social approach behavior, has been
found to be associated with trustworthiness [111] and to
increase trust when administered intranasally [112].
Oxytocin leads to an increase of dopamine levels [113],
and dopamine is thought to be the main neurotransmit-
ter of the reward system [114], which plays an important
role in trust (see above). Recent literature suggests, that
the prosocial effects of oxytocin might be context
dependent in the sense, that oxytocin acts predomin-
antly on behavior towards members participating in a
group in contrast to out-group members [115-117]. Cor-
tisol, a stress hormone, has only recently been associated
with trust and seems to play an antagonistic role to oxy-
tocin [118]. Further, a gender difference in trust has
been proposed, and several surveys show that men trust
more than women, (e.g. [119]). Women also exhibit dif-
ferent brain activation patterns in a trustworthiness
evaluation task [120], and trust related brain areas (e.g.
caudate nucleus) differ in size between the genders
[121]. Furthermore, gender dimorphisms for distrust
have been reported [122].
In marketing research, consumer trust is a key focus.
The perceived trustworthiness of brands is seen as the
main basis for brand loyalty, which indicates a certain
purchase consistency and brand performance [123,124].
Furthermore, research involving trust in advertisements,
as well as trust in online environments (e.g. offers and
websites) has flourished in recent years [120,125-127].
Trust in relationships between marketing operatives (e.g.
industrial purchasers and sellers) is also a key theme in
research [128,129]. However, even though trust is com-
monly cited as a major research topic in consumer
neuroscience (e.g. [29]), experimental data in this area
has mostly been acquired by scientists involved in neu-
roeconomics and decision neuroscience (e.g. [130]).
Implications for neurologists
In recent years, economically-orientated sciences have
shed light on the neurobiology of interpersonal trust
through questionnaires and gaming paradigms. Medicalresearch at the same time has focused on the important
role that trust plays in the patient-physician relationship,
as health outcomes of several diseases have been shown
to be associated with trust in physicians [131,132]. Se-
veral studies also showed a positive impact of a patient’s
trust in physicians on patient satisfaction, therapy adher-
ence and continuity of care [133-135]. Being comforting
and caring, demonstrating competency, answering ques-
tions, and explaining diagnosis and therapy to the patient
has been shown to increase trust [136]. Multiple neuro-
logical diseases lead to an impairment of trust-relevant
brain areas and/or a disequilibrium of associated hor-
mones. Depression leads, on the one hand, to structural
changes in the caudate nucleus and other trust-related
brain areas and, on the other hand, to hypercortisolemia
[137,138], and should therefore theoretically impair trust
on the basis of these two mechanisms. As the reward sys-
tem is part of the brain’s trust network, it seems plausible
that diseases affecting the dopaminergic pathways could
also impair trust behavior. Further, there are several
neurological diseases affecting frontal brain regions, e.g.
frontotemporal dementia and other neurodegenerative
diseases as well as certain types of epilepsy, that could lead
to lower trust. Empirical behavioral data (e.g. using the
trust-game or paradigms, where trust of sale-offers and
brands is assessed) is needed to test this hypothesis and
can be seen as an opportunity for a fruitful collaboration
of neurologists or psychiatrists with researchers in con-
sumer neuroscience. A transfer of knowledge would cer-
tainly be profitable for both sides, as it would lead, on the
one hand, to new insights into the neurobiology of trust.
On the other hand, neurologists could identify diseases
leading to lower trust in physicians and deduce guidelines
to improve communication with, and therapy adherence
of, these patients.
Ethical aspects from a neurological perspective
Marketing-related topics such as target marketing or
consumer vulnerability have traditionally elicited con-
cerns leading to vital scientific and public discussions
about the fundamentals of marketing from an ethical
perspective (see, e.g., [139]). Ethical evaluations of alter-
native concepts, models and methodologies applied in
marketing have created a discourse in both industry and
society. Especially, when it comes to the marketing of
pharmaceutical products [140].
As the field of consumer neuroscience and neuromar-
keting is still new, a comprehensive ethical discussion is
vital. In keeping with this, there is a steadily growing num-
ber of studies dealing with the ethical aspects of neuro-
marketing. Potential ethical dilemmas covered in such
work include whether technology such as neuroimaging
should be employed in an effort to maximize profit [141],
and also whether the findings of neuromarketing research
Javor et al. BMC Neurology 2013, 13:13 Page 7 of 12
http://www.biomedcentral.com/1471-2377/13/13can be seen as a violation of individual consumer rights
such as privacy [67]. Notwithstanding the common confu-
sion over commercial and scientific approaches to neuro-
marketing as discussed previously, consumer neuroscience
on the other hand has to deal with similar ethical pro-
blems as other neuroscientific fields (for an introduction
to general neuroethics we recommend [142]).
The question of whether neuroscientific methods should
be used for the sole purpose of increasing profit can be
seen as the starting point of any ethical consideration
on the subject of neuromarketing [141]. However, any
attempt to commercialize neuroscience should be of inter-
est to neurologists. From a medical perspective, doctors
participating in neuromarketing could lead to a loss of
prestige of physicians in general [21] or to the occurrence
of conflicts of interest. In particular, publication bias, the
phenomenon of positive results being published more fre-
quently than negative results, plays a role in any industry-
sponsored research [143]. Reports suggesting that industry
may alter, obstruct, or stop publication of negative results
have been published [144,145]. These ethical problems
that occurred in studies sponsored by the pharmaceutical
industry might also manifest in neuromarketing studies.
In an ethical sense, neuromarketing should thoroughly
be evaluated based on the potential added-value it might
have for product improvement (for example by better
knowledge of the consumer's preferences), compared to
the sole purpose of maximizing profit [67]. Long-term
entrepreneurial success is a primary objective of most eco-
nomic models. With this in mind, it is natural that it is
also the aim of scientific marketing research to discover as
much as possible about consumer behavior in order to be
able to derive recommendations for improved economic
actions. Therefore, it is necessary to instigate a detailed
ethical discussion about marketing research and practice
and ethical standards [146-150], that includes marketing
scientists, practitioners, ethicists and possibly neurologists,
who could add methodological knowledge and experience
in ethical aspects of clinical research to the discussion.
These standards, on which all parties consent, should
be applicable to marketing research, applied neuromarke-
ting, and scientific research in the field of consumer
neuroscience.
In clinical science, standards of how to protect study
participants and provide security of personal data have
long been established. For example, ethical guidelines
based on the Helsinki Declaration have been institutiona-
lized [151]. However, since they are not classed as medical
research, it is possible that some neuromarketing studies
do not comply with any ethical declarations. Although the
majority of methodologies applied within the frame of
neuromarketing are not physically invasive, detailed infor-
mation provided prior to participation, and written con-
sent given for the use of the results exclusively as stated,are compulsory [67]. All these items should be explicitly
stated in a set of rules [152].
The growing media coverage of the topic of neuromar-
keting has predominantly covered the commonly-feared
idea of ‘mind reading of consumers’ private thoughts and
the location of the so-called ‘buy-button in the brain’.
These misconceptions have their roots primarily in false
promises given by commercial agencies. However, as of
2012, such a ‘buy-button’ has not been found, and it seems
unlikely that such a thing exists in a scientific sense. In
fact, despite consumer fears over neuromarketing, current
marketing practice at the point of sale in traditional retail
or consumer data transactions within the field of data
mining and analytics [153] are likely to be far more ma-
nipulative than neuroscientific experiments could ever be,
given the complexities of the human brain. Even so, while
these commonly-feared ideas seem futuristic, and far be-
yond the limits of current technology, in light of increas-
ingly fast technological development (and widespread
public fears), such a discussion is legitimate [154-163]. An
ethical discourse like this would benefit from the expert
knowledge and experience of neurologists. It is important
in particular for neurologists to enter this debate, and help
clarify what type of information current brain-imaging
methodology is realistically able to provide and how this
information might affect society.
Of special interest to neurologists is the use of neuro-
marketing practice on children and minorities, as well
as ill, disabled, or disadvantaged/powerless individuals.
Most authors agree that they need special protection
[152] and argue that biological disorders must not be
misused by being targeted by specifically-confined mar-
keting activities [67].
The entirety of ethical considerations related to brain
imaging in general is also relevant to consumer neuro-
science. This includes two major issues, both of which
have been subject to ongoing debate among neurologists
in general [164-167]; first, how to tackle unexpected
pathological findings, that are true for about 1% of the
population [168]. Second, issues concerning communi-
cating the findings as completely and truthfully as pos-
sible to the public audience [169]. In neuromarketing
and consumer neuroscience, functional brain imaging is
more common than structural MRI. Even so, as Illes
[170] argues: ‘We must ask, for example, whether all
studies of normative neurobehavioral phenomena are
ethically acceptable. How might social or racial biases
affect applications of the technology, the conditions
under which imaging is performed, or the way interpre-
tations are made? What does a statistically normal acti-
vation pattern of moral behavior really mean, and, by
extension, what would the implication of an abnormal
brain activation pattern be in a healthy person normally
(i.e., within predicted behavioral or physiological norms)
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As a consequence of this ethical debate there are
initiatives arising to attempt the creation of standards
for the use of neurological methods in marketing. On
the one hand, commercial suppliers of neuromarketing
methods are, under the pressure of public attention,
willing to accept the rules of academic research [171]
and on the other hand more and more researchers, like
the group of Plassmann et al. [20], publish recommenda-
tions for the academic community (e.g. avoid redundant
and irrelevant information, employ rigorous experimen-
tal setups and establish standards). There are also initia-
tives establishing rules and guidelines for commercial
neuromarketing studies. For instance, in 2011, ESOMAR
published ‘36 questions to help commission neurosci-
ence research’ [172]. Another initiative to be mentioned
here is the ‘NMSBA Code of ethics for the application of
neuroscience in business’ published by NMSBA in 2012
[173]. In addition to these initiatives, we propose the es-
tablishment of a registry of companies using neuroima-
ging in a commercial setting as well as an ethics
committee, to take an oversight role regarding the stud-
ies run by these companies.
Implications for neurologists
The ethical implications of neuromarketing and con-
sumer neuroscience are important, because neurologists
entering this field must have a basic knowledge in this
area, due to the high media presence and possible public
critique [174]. We argued earlier for a differentiated
view, and proposed the terms ‘neuromarketing’ and ‘con-
sumer neuroscience’, as there are both commercial and
scientific applications of neuroscientific methods in a
marketing context. With this in mind, it is interesting to
note that a recently-published study reports that neurol-
ogists were favorable towards neuromarketing, and
agreed upon it not being a manipulative way of selling
unnecessary goods and services [175]. However, although
most methods used in neuromarketing have a low risk
profile, there is research emerging using more invasive
forms of neurological methodology, such as transcranial
magnetic or direct current stimulation [176,177]. As these
instruments are frequently used in neurological research,
we strongly believe that the entrance of neurologists to
the ethical debate around neuromarketing would be bene-
ficial. Disabled persons have already been identified as a
group for target marketing [178], and as such it only
seems to be a matter of time until neurological patients
come into focus in the same way. As we have shown in
previous sections, several brain systems that are essentially
regulating the reaction to key marketing tools such as
brands and advertising are affected by neurological disor-
ders. Therefore, neurological patients might show specialconsumer vulnerability. To the best of our knowledge
there is no empirical data as to how neurological patients
react to marketing measures. The results of such studies
could be very helpful in initiating an interdisciplinary dis-
cussion about a set of standards and codes of conduct for
commercial marketing actions on our patients.
Summary
Consumer neuroscience has gained considerable insights
in basic functions of the human brain, through application
of neuroscientific methods to marketing research ques-
tions. These findings have found a broad audience in the
scientific community of economists, biologists and psy-
chologists. There are also neurologists and psychiatrists
involved in neuromarketing and consumer neuroscience,
although the general medical neuroscientific community
has only recently started to draw its attention to the find-
ings of this field of research and how they can contribute
to psychiatry [37].
The intention of this paper was to start a similar discus-
sion in the neurological community. We think that espe-
cially the field of behavioral neurology could profit from
collaboration with economists and marketing researchers,
as the neurobiology of behavior is a common interest and
there is theoretical evidence that behavioral symptoms of
neurological diseases could affect consumer behavior and
economic decision-making.
In this article we gave readers an introduction into
scientific and commercial applications of neuroscientific
methods in marketing. We argued for a differentiated
terminology, naming commercial applications ‘neuromar-
keting’ and scientific applications ‘consumer neuroscience’.
Further, we identified a number of key areas where neuro-
logists can gain further insights into the pathophysiology
of neurological diseases and correlated behavioral symp-
toms through an examination of consumption behavior:
First, we think that studies using game paradigms could
help to gain further insights into the underlying pathophysi-
ology of pathological gambling in Parkinson’s disease, fron-
totemporal dementia, epilepsy, and Huntington’s disease.
Second, we identified compulsive buying as a common
interest in neurology and consumer neuroscience. Para-
digms commonly used in consumer neuroscience could
be applied to patients suffering from Parkinson’s disease
and frontotemporal dementia to advance knowledge of
this important behavioral symptom.
Third, trust research in the medical context lacks em-
pirical behavioral and neuroscientific evidence. Neurolo-
gists entering this field of research could profit from the
extensive knowledge of the biological foundation of trust
that consumer neuroscientists have gained.
Fourth, neurologists could contribute significantly to
the ethical debate about invasive methods in neuromar-
keting and consumer neuroscience. Further, neurologists
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neurological patients to marketing and advertising mea-
sures, as they could show special consumer vulnerability
and be subject to target marketing.
Endnotes
a The trust game involves two players each receiving
an amount of money (i.e. 10€). The rules are simple:
Player one can freely decide how much of the given
amount he wants to send to player 2. Every dollar sent is
tripled. Player 2 can then decide how much of the
tripled money to keep and how much to send back to
Player 1. Classic game theory predicts that player 2 will
not send any money back and therefore player 1 will not
send any money in the first place. But this is not what
was observed empirically. On average players sent 5.16$
and counterparts reciprocated in about one third of the
cases by sending back more than they received [100].
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